



Chart Industries Third Quarter 2018

October 18, 2018

Forward Looking Statements



Certain statements made in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning the Company's plans, objectives, future orders, revenues, margins, earnings or performance, liquidity and cash flow, capital expenditures, business trends, and other information that is not historical in nature. Forward-looking statements may be identified by terminology such as "may," "will," "should," "could," "expects," "anticipates," "believes," "projects," "forecasts," "outlook," "guidance," "continue," or the negative of such terms or comparable terminology.

Forward-looking statements contained in this presentation or in other statements made by the Company are made based on management's expectations and beliefs concerning future events impacting the Company and are subject to uncertainties and factors relating to the Company's operations and business environment, all of which are difficult to predict and many of which are beyond the Company's control, that could cause the Company's actual results to differ materially from those matters expressed or implied by forward-looking statements. Factors that could cause the Company's actual results to differ materially from those described in the forward-looking statements include: those found in Item 1A (Risk Factors) in the Company's most recent Annual Report on Form 10-K filed with the SEC, which should be reviewed carefully; Chart's ability to close the VRV acquisition, successfully integrate VRV, and achieve anticipated revenue, earnings and accretion; estimated segment revenues, future revenue, earnings, cash flows, and margin targets and run rates; and Chart's ability to close the sale of its oxygen-related products business within the BioMedical segment. The Company undertakes no obligation to update or revise any forward-looking statement.

Chart is a leading diversified global manufacturer of highly engineered equipment for the industrial gas, energy, and biomedical industries. The majority of Chart's products are used throughout the liquid gas supply chain for purification, liquefaction, distribution, storage and end-use applications, a large portion of which are energy-related. Chart has domestic operations located across the United States and an international presence in Asia, Australia, Europe and Latin America. For more information, visit: <http://www.chartindustries.com>.


Third Quarter 2018 Financial Results



Sales & Revenue¹


(\$USD Million)

\$272




Earnings Per Share¹

\$0.65



Adjusted Earnings Per Share^{1,2}

\$0.74



Q3 Highlights

- Sales increase of 34.3% over the third quarter of 2017, 16.0% excluding Hudson Products
- Reported earnings per diluted share increased \$0.67 compared to the third quarter 2017, and adjusted EPS grew \$0.52 in the same comparative period
- Orders of \$264 million increased compared to \$217 million in the third quarter of 2017, and increased 3.3% organically

1. All results reflect Continuing Operations

2. Adjusted earnings per share is a non-GAAP measure, see reconciliation to the comparable GAAP measure on page 5.

Chart Significant LNG Opportunities



Innovation. Experience. Performance.®

Project Opportunity	Chart Customer	Operator	Country	Capacity	Scope of Supply
PA ssLNG	Confidential	Confidential	USA	50,000 gpd	C50N Cold box, BAHX, ACHX
FL ssLNG Expansion	EPC TBD	Confidential	USA	250,000 gpd	C250N, Cold boxes, BAHX, ACHX
MA ssLNG	Confidential	Confidential	USA	250,000 gpd	C250N, Cold boxes, BAHX, ACHX
Driftwood LNG	Becthel	Tellurian	USA	26 MTPA	IPSMR®, Cold boxes, BAHX, ACHX
Calcasieu Pass	GE	Venture Global	USA	10 MTPA	9 Trains - 2xCold Boxes/train, BAHX
Corpus Christi TX - Stage 3	KBR/Siemens	Cheniere	USA	9.5 MTPA	IPSMR®, Cold boxes, BAHX, ACHX
Gimi (FLNG #3)	Black & Veatch	Golar	W. Africa	3.75 MTPA	4x Cold Boxes, BAHX
PA MultiTrain LNG	EPC TBD	Confidential	USA	3 MM gpd	IPSMR®, Cold boxes, BAHX, ACHX
Magnolia LNG	Magnolia	Magnolia	USA	8 MTPA	Cold Boxes, BAHX, Core-in-kettles
FL ssLNG	EPC TBD	Confidential	USA	500,000 gpd	C500 IPSMR®, Cold boxes, BAHX, ACHX, Tanks
Gandria (FLNG #2)	Black & Veatch	Golar	W. Africa	3.75 MTPA	4x Cold Boxes, BAHX
Pointe LNG	EPC TBD	Pointe LNG	USA	6 MTPA	IPSMR®, Cold boxes, BAHX, ACHX
SE Asia LNG	EPC TBD	Confidential	SE Asia	3 MTPA	IPSMR®, Cold boxes, BAHX, ACHX
SE Asia Expansion	EPC TBD	Confidential	SE Asia	8 MTPA	IPSMR®+, Cold boxes, BAHX, ACHX

2018 YTD Financial Results



Sales & Revenue¹
(\$USD Million)
\$794

Earnings Per Share¹
\$1.11

**Adjusted
Earnings Per Share^{1,2}**
\$1.41



YTD Q3 2018 Highlights

- Sales increase of 38.5% over YTD third quarter of 2017, 16.2% excluding Hudson Products
- Reported earnings per diluted share increased \$1.15 compared to the first three quarters of 2017, and adjusted EPS grew \$1.06 in the same comparative period
- Orders of \$869 million increased compared to \$613 million in the first three quarters of 2017, and increased 14.4% organically

1. All results reflect Continuing Operations

2. Adjusted earnings per share is a non-GAAP measure, see reconciliation to the comparable GAAP measure on page 5.

Adjusted Earnings Per Share



Innovation. Experience. Performance.®

<i>\$ millions, except per share amounts</i>	Q3 2018	Q3 2017	Change V. PY	YTD 2018	YTD 2017	Change V. PY
<i>Net income (loss) from continuing operations</i>	\$21.5	(\$0.6)	\$22.1	\$35.6	(\$1.2)	\$36.8
EPS (1) <i>from continuing operations</i>	\$0.65	(\$0.02)	\$0.67	\$1.11	(\$0.04)	\$1.15
<i>Restructuring and transaction- related costs</i>	\$0.07	\$0.24	(\$0.17)	\$0.16	\$0.39	(\$0.23)
<i>Aluminum cryobiological tank recall reserve expense</i>	-	-	-	0.09	-	0.09
<i>CEO departure net costs</i>	-	-	-	0.03	-	0.03
<i>Dilution impact of convertible notes</i>	0.02	-	0.02	0.02	-	0.02
Adjusted EPS (2,3) <i>from continuing operations</i>	\$0.74	\$0.22	\$0.52	\$1.41	\$0.35	\$1.06

(1) On January 1, 2018, we adopted ASC 606 which resulted in a timing related EPS impact of \$0.00 Q3 2018, and \$0.03 YTD 2018.

(2) Adjusted EPS (a non-GAAP measure) is as reported on a historical basis.

(3) Adjusted EPS normalized for FX impact would have been \$0.73 and \$0.26 for Q318 and Q317, or \$1.42 and \$0.41 YTD 2017 and 2018 respectively.

(4) Tax effected adjustments are at normalized statutory quarterly rates.

2018 Financial Results Recap



Innovation. Experience. Performance.®

<i>\$ millions, except per share amounts</i>	Q3 2018 Revenue	Q3 2018 Net Income	Q3 2018 EPS	Adjustments	Q3 2018 Adjusted EPS
<i>Chart Industries, Consolidated</i>	\$315.2	\$22.2	\$0.67	\$0.09	\$0.76
<i>Less: Discontinued Operations</i>	43.0	0.7	0.02	-	0.02
<i>Chart Industries, Continuing Operations</i>	\$272.2	\$21.5	\$0.65	\$0.09	\$0.74

<i>\$ millions, except per share amounts</i>	YTD 2018 Revenue	YTD 2018 Net Income	YTD 2018 EPS	Adjustments	YTD 2018 Adjusted EPS
<i>Chart Industries, Consolidated</i>	\$914.8	\$40.3	\$1.25	\$0.30	\$1.55
<i>Less: Discontinued Operations</i>	120.6	4.7	0.14	-	0.14
<i>Chart Industries, Continuing Operations</i>	\$794.2	\$35.6	\$1.11	\$0.30	\$1.41

2018 Guidance



Innovation. Experience. Performance.®

Prior Guidance (Q2 2018)¹

Sales
\$1.20B - \$1.25B
7-9% organic growth

Adjusted EPS
\$1.85 - \$2.05
*Inclusive of ~\$0.15 impact from U.S. tax reform
Assumes 27% full year tax rate*

Capital Expenditures
\$35M - \$45M
Inclusive of ~\$11M for finalization of La Crosse, WI capacity expansion

Prior Guidance, Q2 2018, Continuing Ops²

Sales
\$1.04B - \$1.09B

Adjusted EPS
\$1.64 - \$1.84

Capital Expenditures
\$34M - \$44M
Inclusive of ~\$11M for finalization of La Crosse, WI capacity expansion

FY 2018 Guidance²

Sales
\$1.06B - \$1.10B

Adjusted EPS
\$1.90 - \$2.00

Capital Expenditures
\$35M - \$40M
Inclusive of ~\$11M for finalization of La Crosse, WI capacity expansion

1. The Company's prior guidance assumed continued ownership of all assets for the entire calendar year.
2. The Company's current guidance reflects continuing operations only, and prior guidance restated to reflect continuing operations only.

2019 First Look at Guidance



Full Year 2019

Sales
\$1.24B - \$1.30B
16-%18% growth
6%-7% organic growth

Adjusted EPS
\$2.40 - \$2.75
Assumes 22% to 23% full year tax rate
Excludes any large LNG related revenue
Includes Full Year of VRV, s.p.a. and Excludes CAIRE

Capital Expenditures
\$30M - \$40M